Skip to content

Erythromycin Versus Gastric Lavage to Improve Quality of Endoscopy in Patients With Upper Gastrointestinal Bleeding

Erythromycin Versus Gastric Lavage to Improve Quality of Endoscopic Examination in Patients With Upper Gastrointestinal Bleeding. A Prospective Randomized Trial.

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01716572
Enrollment
122
Registered
2012-10-30
Start date
2012-02-29
Completion date
2015-12-31
Last updated
2015-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Hemorrhage, Hematemesis

Keywords

Upper gastrointestinal bleeding, Endoscopy, Erythromycin, Gastric lavage

Brief summary

The researchers will investigate whether erythromycin infusion is better than gastric lavage prior to emergency endoscopy to improve the quality of examination in patients with upper gastrointestinal bleeding.

Detailed description

The researchers will investigate whether erythromycin infusion is better than gastric lavage prior to emergency endoscopy to improve the quality of examination in patients with upper gastrointestinal bleeding. One hundred and twenty-two patients admitted within 12 hours after hematemesis will be randomly assigned to receive erythromycin infusion or gastric lavage by nasogastric tube prior to emergency endoscopy. The endoscopic procedures will be recorded on Digital Video Disc (DVD). Two endoscopists blinded to the cleansing strategy will assess the quality of examination of the upper gastrointestinal tract by using scales designed by Frossard and Avgerinos . Secondary endpoints will be the need for a second-look endoscopy, the mean number of blood units transfused, the need of surgery or arteriography, and the mean duration of hospitalization

Interventions

DRUGErythromycin

Intravenous 250 mg of erythromycin, single-dose, 30 minutes before the endoscopy

gastric lavage by nasogastric tube with 1 liter of saline before the endoscopy

Sponsors

Ministerio de Sanidad, Servicios Sociales e Igualdad
CollaboratorOTHER_GOV
Hospital Universitari de Bellvitge
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* recent hematemesis (\<12 hours)

Exclusion criteria

* macrolides allergy * pregnancy or lactation * treatment with terfenadine, astemizole or cyclosporine * prior gastrectomy

Design outcomes

Primary

MeasureTime frameDescription
Visual quality of endoscopyThe endoscopy will be recorded and subsequently it will be evaluated by two endoscopists unaware of the cleaning strategy. The recording's evaluation will be made within the first 30 days after endoscopyTo assess the visual quality of endoscopy the investigators will use the Avgerinos' score modified by Frossard (Gastroenterology 2002;123:17-23). An score from 0 to 2(0 worst vision, where \< 25% of the surface was visible. 1, 25-75% visible and 2 \>75% visible) was derived from analysis of each area (fundus, body, antrum and bulbus). A score of 6 or greater is considered as a clear stomach, and a score of 5 or lower was considered as a full stomach.

Secondary

MeasureTime frameDescription
need for arteriography or surgerywithin the first 30 days after endoscopy
number of adverse events as a measure of safety and tolerabilitywithin the first 30 days after endoscopy
length of endoscopic procedurewithin the first 30 days after endoscopy
need for a second-look endoscopywithin the first 30 days after endoscopyTo assess the need of a second-look endoscopy due to a full stomach during the first endoscopy or due to rebleeding
need of blood transfusionwithin 30 days after endoscopy
length of hospitalisationwithin the first 30 days after endoscopy

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026